Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma

Podobne zapisy

• Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma
  od: Peters, Katherine B., i wsp.
  Wydane: (2015)
• The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide and Irinotecan for Newly Diagnosed Glioblastoma
  od: Vredenburgh, James J., i wsp.
  Wydane: (2011)
• Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients
  od: Reardon, David A., i wsp.
  Wydane: (2011)
• AT-22 PHASE II TRIAL OF BEVACIZUMAB, RADIATION THERAPY (RT) AND TEMOZOLOMIDE FOLLOWED BY BEVACIZUMAB AND TEMOZOLOMIDE WITH CONTINUATION OF BEVACIZUMAB BEYOND PROGRESSION
  od: Ghiaseddin, Ashley, i wsp.
  Wydane: (2014)
• Phase II study of carboplatin, irinotecan and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
  od: Reardon, David A., i wsp.
  Wydane: (2011)